Publicaciones en colaboración con investigadores/as de Universitat Autònoma de Barcelona (21)

2024

  1. High-Fat Diet-Induced Obesity Increases Brain Mitochondrial Complex I and Lipoxidation-Derived Protein Damage

    Antioxidants, Vol. 13, Núm. 2

2023

  1. Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis

    Brain Communications, Vol. 5, Núm. 2

  2. Low adherence to the Mediterranean diet is associated with increased prevalence and number of atherosclerotic plaques in the ILERVAS cohort

    Atherosclerosis, Vol. 380

2022

  1. Cardiac fibroblasts display endurance to ischemia, high ROS control and elevated respiration regulated by the JAK2/STAT pathway

    FEBS Journal, Vol. 289, Núm. 9, pp. 2540-2561

  2. Prediabetes Is Associated with Increased Prevalence of Sleep-Disordered Breathing

    Journal of Clinical Medicine, Vol. 11, Núm. 5

  3. Seroprevalence of SARS‐CoV‐2 in a Cohort of Patients with Multiple Sclerosis under Disease‐Modifying Therapies

    Journal of Clinical Medicine, Vol. 11, Núm. 9

2021

  1. Assessing blood-based biomarkers to define a therapeutic window for natalizumab

    Journal of Personalized Medicine, Vol. 11, Núm. 12

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. REMOTE Ischemic Perconditioning Among Acute Ischemic Stroke Patients in Catalonia: REMOTE-CAT PROJECT

    Frontiers in Neurology, Vol. 11

2019

  1. Mitochondrial m.13513G > A Point Mutation in ND5 in a 16-Year-Old Man with Leber Hereditary Optic Neuropathy Detected by Next-Generation Sequencing

    JOURNAL OF PEDIATRIC GENETICS, Vol. 8, Núm. 4, pp. 231-234

  2. Th1Th17CM lymphocyte subpopulation as a predictive biomarker of disease activity in multiple sclerosis patients under dimethyl fumarate or fingolimod treatment

    Mediators of Inflammation, Vol. 2019

2018

  1. Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients

    CNS Neuroscience and Therapeutics, Vol. 24, Núm. 12, pp. 1175-1184

2017

  1. PEY could control neuroflammation and aging

    APPROACHES TO AGING CONTROL, pp. 57-61

2016

  1. Targeted activation of CREB in reactive astrocytes is neuroprotective in focal acute cortical injury

    GLIA, Vol. 64, Núm. 5, pp. 853-874

2014

  1. Resveratrol Improves Motoneuron Function and Extends Survival in SOD1G93A ALS Mice

    Neurotherapeutics, Vol. 11, Núm. 2, pp. 419-432

2011

  1. Interferon beta-1b for the treatment of primary progressive multiple sclerosis: Five-year clinical trial follow-up

    Archives of Neurology, Vol. 68, Núm. 11, pp. 1421-1427

2010

  1. Bologna Process (II): Centered education learning

    Educacion Medica, Vol. 13, Núm. 4, pp. 197-203

2008

  1. Signalling by neurotrophins and hepatocyte growth factor regulates axon morphogenesis by differential β-catenin phosphorylation

    Journal of Cell Science, Vol. 121, Núm. 16, pp. 2718-2730

2006

  1. The decrease of NAD(P)H has a prominent role in dopamine toxicity

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1762, Núm. 5, pp. 564-574

1995

  1. Age-related fluorescence in rat lung collagen

    Lung, Vol. 173, Núm. 3, pp. 177-185